BofA raises Gilead Sciences stock price target on positive trial data
BofA raises Gilead Sciences stock price target on positive trial data Investing.com
Covered in this story
Call it yourself
No calls on $GILD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Gilead Sciences →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.